Complement Antagonists Modulating B Cell Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for B cell-mediated disorders, such as autoimmune diseases and leukemias, are inadequate as they only ameliorate symptoms without curing the disease, and existing vaccination strategies struggle to effectively modulate B cell responses for infectious diseases like Ebola and Malaria.
Innovation Solution
Administering agents that modulate C3aR and C5aR signaling in B cells, either by inhibiting or promoting their activity, using complement antagonists or agonists to regulate B cell responses, which can include antibodies, polypeptides, or RNA interference to target C3a and C5a receptors, thereby influencing B cell activity, proliferation, and antibody production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for B cell-mediated disorders are used, then symptoms are ameliorated, but the disease is not cured and excessive B cell activity persists
Solution Approach 1:
The patent uses complement antagonists (such as anti-C3aR or anti-C5aR antibodies) as intermediary substances that block the interaction between complement anaphylatoxins (C3a, C5a) and their receptors on B cells. This intermediary approach prevents the harmful signaling pathway while maintaining other essential B cell functions, thereby addressing the contradiction between curing the disease and managing B cell activity.
Solution Approach 2:
The patent modifies the signaling parameters of B cells by specifically inhibiting C3aR and C5aR pathways through complement antagonists. This selective parameter change allows normalization of excessive B cell activity without completely suppressing B cell function, thus achieving disease cure while maintaining necessary immune responses.
2Productivity
If existing vaccination strategies are used, then some immune response is generated, but B cell responses are not effectively modulated for infectious diseases
Solution Approach 1:
The patent introduces complement antagonists as intermediary molecules that can be combined with vaccines to modulate B cell responses. These antagonists act as mediators that enhance or redirect the vaccine-induced immune response, improving both antibody production and overall vaccine effectiveness against infectious diseases.
Solution Approach 2:
The patent employs dynamic modulation of B cell responses by using complement antagonists that can be administered in controlled amounts and timing alongside vaccination. This dynamic approach allows optimization of the immune response trajectory, enhancing antibody production while maintaining vaccine effectiveness through adjustable intervention.
Data Source
AI summary
A method of treating a B cell mediated disorder in a subject in need thereof, the method includes administering to B cells of the subject at least one agent that inhibits C3 aR and/or C5 aR signaling of the B cells.